Skip to main content
PLOS Computational Biology logoLink to PLOS Computational Biology
. 2025 Feb 11;21(2):e1012825. doi: 10.1371/journal.pcbi.1012825

A model of Notch signalling control of angiogenesis: Evidence of a role for Notch ligand heterodimerization

Daipeng Chen 1,2,‡, Xinxin Liu 3,‡, Haijiang Wang 3,4,‡, Roeland MH Merks 2,5, David A Baker 3,*
Editor: James R Faeder6
PMCID: PMC11841921  PMID: 39932958

Abstract

The ubiquitous Notch receptor signalling network is essential for tissue growth and maintenance. Operationally, receptor activity is regulated by two principal, counterposed mechanisms: intercellular Notch transactivation triggered by interactions between receptors and ligands expressed in neighbouring cells; intracellular cis inhibition mediated by ligands binding to receptors expressed in the same cell. Moreover, different Notch receptor/ligand combinations are known to elicit distinct molecular and cellular responses, and together, these phenomena determine the strength, the duration and the specificity of Notch receptor signalling. To date, it has been assumed that these processes involve discrete ligand homomers and not heteromeric complexes composed of more than one ligand species. In this study, we explore the molecular basis of the opposing actions of the Notch ligands, DLL4 and JAG1, which control angiogenic sprouting. Through a combination of experimental approaches and mathematical modelling, we provide evidence that two mechanisms could underpin this process: 1) DLL4 rather than JAG1 induces efficient Notch1 receptor transactivation; 2) JAG1 directly blocks DLL4-dependent cis-inhibition of Notch signalling through the formation of a JAG1/DLL4 complex. We propose a new model of Notch signalling that recapitulates the formation of tip and stalk cells, which is necessary for sprouting angiogenesis.

Author summary

The ancient Notch signalling pathway is a central regulator of metazoan cell fate, and corruption of it has been implicated in numerous diseases including the majority of solid tumours. Since its discovery in the second decade of the last century one central question to emerge is how such a wide range of different cellular/physiological processes can be governed by such a relatively simple repertoire of Notch receptors and ligands. In this study, using a combination of experimental approaches and mathematical modelling, we provide the first evidence that Notch ligands can directly bind to each other, and that this novel mechanism of ligand heterodimerization could help determine the strength, the duration and the specificity of Notch signalling. Our model faithfully recapitulates both our presented experimental results as well as the recently published work of others, and provides a novel perspective for understanding Notch-regulated biological processes, most notably angiogenesis.

Introduction

The ancient and highly conserved Notch receptor signalling pathway is indispensable for embryonic and post-embryonic tissue growth and development [1,2]. It is formed of large (approximately 300 kDa) single pass cell membrane receptors, and ligands which can also be expressed at the cell surface. The overall size, structure and known function of these core receptor/ligand components has remained relatively unchanged over evolutionary time although the number of Notch receptor and ligand family members encoded by different genera varies, for example, invertebrates such as Drosophila possess a single type of Notch receptor controlled by two distinct ligands, whilst vertebrates express up to four distinct receptor paralogues (Notch1–4) and five different ligands: Jagged (JAG)1, JAG2, Delta-Like (DLL)1, DLL3, and DLL4 [3]. Uniquely amongst cell surface receptors, Notch itself can directly activate gene transcription as part of a DNA-bound activation complex, a signal triggered via a trans interaction between the extracellular domain of the receptor and Notch ligands expressed by neighbouring cells. Upon ligand binding, the resultant biomechanical strain/pulling forces cause structural changes which expose specific enzyme cleavage sites in the membrane-proximal region of the receptor [4–8]. Subsequently, a defined series of proteolytic events terminates in the γ-secretase-mediated cleavage of the Notch intracellular domain [9,10], which translocates to the nucleus whereupon it stimulates expression of Notch target genes [11,12]. An important counterbalance to Notch signalling transactivation is a regulatory mechanism termed cis-inhibition by which ligands block the activity of receptors expressed in the same cell [13–15]. Thus, in this view, the net receptor signalling output is determined by the relative ‘strength’ of these two counterposed processes (transactivation and cis-inhibition).

Whilst, the basic features of Notch receptor transactivation, outlined above, have been delineated in some detail, a number of fundamental issues remain enigmatic. One question relates to the precise nature and significance of cis inhibition and how it counteracts receptor transactivation. Another central question concerns how the manifold potential receptor-ligand combinations will give rise to the different signalling outputs necessary for tissue patterning. In this context, recent work has dissected, at the molecular level, the cellular responses to different ligands, which can stimulate either discrete pulses of Notch activity (in the case of DLL1) or a sustained period of signalling (in the case of DLL4) yielding distinct gene expression outcomes [16,17]. At the tissue level, a classic example of the divergent roles of different Notch ligands is found during sprouting angiogenesis wherein DLL4 was shown to constrain sprouting opposed by the pro-angiogenic properties of JAG1 [18,19]. Of significant interest, in this in vivo setting, was the notion that JAG1 functions by antagonizing the activity of DLL4, highlighting the possibility of crosstalk/competition between the ligands, though the specific molecular details have not been elucidated.

In this light, other potential facets of Notch signalling merit consideration. For instance, in the absence of available evidence, it has been generally assumed that cis and trans receptor/ligand interactions are essentially monomeric in nature, and involve binding of one species of ligand and a single species of receptor rather than complexes of different receptor types, or different ligand types. There are, however, reasons to suppose that the actual picture may be more complicated. Both receptors and ligands harbour multiple EGF-like repeats, which are known to mediate protein-protein interactions [20], and we have recently shown that homomeric DLL4 ligand complexes could promote cis inhibition of Notch receptor activity [15]. Moreover, the fact that all Notch ligands share a common overall architecture raises the possibility of a potential biological role for heteromeric ligand complex formation, until now, a mechanism which has not been reported.

In this study, we combine experimental approaches and mathematical modelling to explore the molecular control of Notch1 receptor activity by the ligands, DLL4 and JAG1. Our work uncovers a previously overlooked role for heteromeric JAG1/DLL4 complexes, which could enable angiogenic sprouting by regulating the functional differentiation of endothelial cells into leading edge tip cells and trailing stalk cells.

Results

It is established that angiogenic sprouting results from the differential regulation of Notch1 receptor activity by DLL4 and JAG1 (see [18,19]). To understand the molecular details of this mechanism we first investigated the possible biochemical interactions which could control this process.

DLL4 but not JAG1 efficiently stimulates transactivation of Notch1

To test the relative Notch receptor transactivation potential of the ligands DLL4 and JAG1, we performed quantitative reporter assays. Fig 1A shows that whilst DLL4 (and JAG2) efficiently promoted Notch1 transactivation, JAG1 was unable to elicit detectable Notch1 transactivation. Conversely, Fig 1B shows that JAG1 could induce transactivation of Notch2 and Notch3 suggesting that the transactivation block is specific to Notch1. To elucidate a possible molecular basis of this difference we assessed binding of the ligands to Notch receptors expressed at the cell surface. Fig 1C and 1D show that DLL4, but not JAG1, bound relatively efficiently to Notch1 (Fig 1C). In contrast to its lack of binding to Notch1, JAG1 efficiently associated with both Notch2 and Notch3 (Fig 1D). Collectively, these data demonstrate that DLL4, can bind to and effectively trigger Notch1 receptor transactivation, whereas JAG1 fails to bind to the Notch1 receptor with sufficiently high affinity to elicit robust receptor transactivation.

Fig 1. DLL4, but not JAG1, efficiently stimulates Notch1 transactivation.

Fig 1

(A) Luciferase reporter assays were performed as described in the Methods, and depicted schematically (left panel). (B) As illustrated in (A), 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch receptor or ligand constructs (Receiving cells) were co-cultured with cells stably expressing either DLL4 or JAG1 (sender cells) to enable transactivation. For each analysis, reporter activity was normalized using Renilla luciferase. Protein expression levels were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown. (C) Cell surface ligand-receptor binding assays were performed as described in the Methods, and depicted schematically. Cells stably expressing HA epitope tagged Notch1 were incubated with or without the indicated HIS epitope tagged ligand. Complexes were resolved by immunoprecipitation using an anti-HA antibody. Total receptor protein levels and ligand-receptor binding was determined by Western blotting using the indicated antibodies (anti-HA for the receptors, anti-HIS for the ligands). (D) To compare the relative levels of JAG1 binding to either Notch1, Notch2 or Notch3, cells stably expressing (separately) HA epitope tagged versions of each Notch paralogue, were incubated with HIS epitope tagged JAG1. Complexes were resolved by immunoprecipitation using an anti-HA antibody. Total receptor protein levels and ligand-receptor binding was determined by Western blotting using the indicated antibodies (anti-HA for the receptors, anti-HIS for the ligands).

We next explored the respective roles of DLL4 and JAG1 in Notch1 cis inhibition.

DLL4 but not JAG1 promotes strong cis inhibition of Notch1 receptor signalling

Fig 2A shows that DLL4, as expected, potently blocked transactivation of Notch1 when both Notch1 and DLL4 are expressed in the same cell (cis inhibition; see [13]). By comparison, JAG1 could not similarly induce strong (cis) inhibition of Notch1 signalling (Fig 2A), whereas the closely related JAG2 ligand, in common with DLL4, promoted strong cis inhibition of Notch1 activity. We have previously shown that DLL4-dependent cis inhibition of Notch activity requires ligand dimerization/oligomerization (herein referred to simply as dimerization) [15]. In this light, we compared DLL4, JAG2 and JAG1 ligand dimerization. In agreement with our prior observations, both DLL4 and JAG2 could biochemically self-associate, however, JAG1 could not detectably form homodimers, which could explain the observed differences in their relative effectiveness in Notch1 receptor cis inhibition (Fig 2B). The difference between JAG1 and JAG2 was particularly surprising since they display a high degree of overall structural similarity. Indeed, the only significant difference between the two ligands is a von Willebrand factor type C (VWFC) domain located in the juxtamembrane region of the JAG2 extracellular domain (Fig 2C). Two lines of evidence support the idea that homodimer formation by DLL4 and JAG2 is a prerequisite for full Notch1 cis inhibition, and that JAG1 cannot induce full Notch1 cis inhibition because it cannot form homodimers. First, deletion of the JAG2 VWFC domain blocked homodimer formation (Fig 2D). This is consistent with previous studies which have shown, for different proteins, that the VWFC domain can mediate protein oligomerization [21]. Thus, in the absence of the VWFC domain, with respect to ligand self-association, JAG2 exhibits biochemical characteristics comparable to JAG1. Second, deletion of the JAG2 VWFC domain abrogated JAG2-dependent cis inhibition of Notch1 to a degree comparable to JAG1 (Fig 2E). It is notable that in contrast to the relatively weak trans Notch1-JAG1 binding, JAG1 can bind relatively efficiently to Notch1 in cis (see S1 Fig), consistent with the view that the lack of JAG1-mediated cis inhibition of Notch1 does not result from a lack of cis receptor-binding, but is due to the fact that JAG1 cannot form homodimers, which is necessary for cis inhibition (see [15]).

Fig 2. DLL4 (and JAG2), but not JAG1, efficiently mediates Notch1 receptor cis inhibition.

Fig 2

(A) Luciferase reporter assays were performed as described in the Methods, and depicted schematically (left panel). 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch receptor or ligand constructs (Receiving cells) were co-cultured with cells stably expressing DLL4 (sender cells) to enable transactivation. For each analysis, reporter activity was normalized using Renilla luciferase. Protein expression levels were determined by Western blotting of cell lysates (see S9 Fig). Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown. (B) DLL4 (and JAG2), but not JAG1, can efficiently self-associate. The indicated combinations of HA and HIS epitope tagged versions of either DLL4, JAG1 or JAG2 were transfected into 293T cells. Ligand complexes were resolved by immunoprecipitation using Nickel-NTA agarose (which binds HIS6 epitope-tagged ligands) and visualized by Western blotting with the shown antibodies. (C) Schematic representation of the JAG1 and JAG2 ligands highlighting the von Willebrand factor type C (VWFC) domain. (D) The VWFC domain mediates JAG2 self-association. As in (B), the indicated combinations of HA and HIS epitope tagged versions of either JAG1 or JAG2 were transfected into 293T cells. The JAG2-Δ(VWFC) construct lacks the VWFC domain. Ligand complexes were resolved by immunoprecipitation using Nickel-NTA agarose (which binds HIS6 epitope-tagged ligands) and visualized by Western blotting with the shown antibodies. (E) The VWFC is necessary for efficient JAG2-depedent cis inhibition of Notch1. Luciferase reporter assays were performed as described in (A).

In sum, these data suggest that JAG1, uniquely for Notch ligands, fails to form homodimers/oligomers resulting in an inability to effect full cis inhibition of Notch1 receptor signalling.

JAG1 directly blocks DLL4-mediated cis inhibition of Notch1 receptor signalling via the formation of a heteromeric JAG1/DLL4 complex

A seminal study revealed that JAG1 antagonism of the function of DLL4 determines the balance between tip cells and stalk cells necessary for normal capillary sprouting during mouse retina blood vessel development [18], although it is not yet clear if this is via direct/indirect means or at which level of Notch signalling JAG1 acts (receptor transactivation, receptor cis inhibition or both). It is known that the tip cells of the angiogenic front of the growing plexus of the mouse retina express high levels of DLL4 (and lack JAG1 expression) whilst the neighbouring stalk cells express both DLL4 and JAG1 [18]. Accordingly, to investigate the possible biochemical interactions, which might be involved in this process, we first tested Notch1 receptor activity in cells expressing both JAG1 and DLL4, in response to DLL4 expressed on neighbouring cells (see Fig 3A). Fig 3B shows that alone, as expected (see Fig 2), DLL4, but not JAG1, efficiently blocked Notch1 receptor transactivation (cis inhibition). Strikingly, when DLL4 and JAG1 are co-expressed, there is a near-complete release of the block to receptor transactivation (Fig 3B), whereas co-expression of JAG2 had no measurable impact on DLL4-mediated cis inhibition, suggesting this effect is strictly JAG1-dependent (see Fig 3B). To determine if this effect is indirect or instead results from a direct interaction between the JAG1 and DLL4 ligands, we assessed if the ligands could (biochemically) associate. Fig 3C and 3D show that DLL4 and JAG1 can form a complex (Fig 3C) and that EGF-like repeat 7 (in the proximity of the transmembrane domain) of DLL4 is necessary for this interaction (Fig 3D). We surmised that if direct binding of JAG1 to DLL4 is necessary to block cis inhibition to enable efficient Notch1 transactivation, a DLL4 mutant lacking EGF-like repeat 7 (which cannot form a complex with JAG1, see Fig 3D), would be resistant to the effects of JAG1 expressed in the same cell and execute full cis inhibition of Notch1 signalling. Fig 3E (and S2 Fig) show that this is the case, that is, the level of Notch1 receptor cis inhibition in the presence of a combination of mutant DLL4 (lacking EGF-like 7) and JAG1 is similar to the level of cis inhibition mediated by DLL4 alone, resulting in a block to DLL4-mediated Notch cleavage (S2 Fig) and transactivation (Fig 3E) in these cells.

Fig 3. A DLL4-JAG1 heterodimer blocks DLL4-mediated Notch1 receptor cis inhibition and enables efficient Notch1 receptor transactivation.

Fig 3

(A) Luciferase reporter assays were performed as described in the Methods, and depicted schematically (left panel). (B) 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch receptor and ligand constructs (to represent stalk cells) were co-cultured with cells stably expressing DLL4 (to represent tip cells) to enable receptor transactivation. The JAG2-Δ(VWFC) construct lacks the VWFC domain. For each analysis, reporter activity was normalized using Renilla luciferase. Protein expression levels were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown. (C) Biochemical mapping of the DLL4-JAG1 heterodimerization motif. The indicated epitope tagged constructs were transfected into 293T cells (a schematic representation of the constructs is shown - left panel). Ligand complexes were resolved by immunoprecipitation using Nickel-NTA agarose (which binds HIS6 epitope-tagged ligands) and visualized by Western blotting with the shown antibodies. (D) The DLL4 EGF-like repeat 7 (see C), is necessary for DLL4-JAG1 heterodimerization. The indicated epitope tagged constructs were transfected into 293T cells. DLL4-(EGF7) and DLL4-(EGF8) lack the EGF-like repeat 7 and the EGF-like repeat 8 (see C), respectively. Ligand complexes were resolved by immunoprecipitation using Nickel-NTA agarose (which binds HIS6 epitope-tagged ligands) and visualized by Western blotting with the shown antibodies. (E) Cis DLL4-JAG1 heterodimerization enables Notch1 receptor transactivation. Luciferase reporter assays were performed as described in (B) and are displayed schematically (right panel).

These data argue that a heteromeric JAG1/DLL4 complex, formed when the ligands are expressed in the same cell, relieves Notch1 receptor cis inhibition and thereby enables efficient Notch1 receptor signalling.

Overall, our experimental work raises the possibility that two factors could underlie the mechanism by which JAG1 antagonizes DLL4 to enable appropriate tip and stalk cell selection to drive angiogenic sprouting. One, in agreement with prior work [16], DLL4, but not JAG1, can bind to Notch1 (in trans) with sufficiently high affinity to stimulate receptor activation. Two, JAG1 directly blocks DLL4-mediated cis inhibition, via the formation of a heteromeric DLL4/JAG1 complex, which allows transactivation of Notch receptors expressed in the same cell.

Modelling DLL4/JAG1-Notch signalling

To explore the potential biological implications of our biochemical findings presented above, we extended our earlier theoretical model of DLL4-Notch signalling [15] to produce a new model which takes account of the observed differences in affinity of the Notch1 receptor for (trans) DLL4 and (trans) JAG1, as well as heteromeric DLL4/JAG1 complex formation. In any given cell, the new model is presented mathematically as Eq. (1),

dDdt=bD−βD−2khoD2−kheJD−ktNextD,dJdt=bJ−βJ−kheDJ−αktNextJ,dCdt=khoD2−βC−kciNC,dNdt=bN−βN−kciCN−ktDextN−αktJextN,dSdt=ktDextN+αktJextN−βSN, (1)

where bD, bJ and bN denote the production rates of DLL4 (D), JAG1 (J) and Notch1 receptor (N), respectively. The variable C indicates the amount of DLL4 homodimers, and kho represents the rate of DLL4-DLL4 dimerization. The heterodimer of DLL4 and JAG1 is an inactive complex, and khe represents the rate of DLL4-JAG1 dimerization. The proteins described in the model are assumed to be degraded at a constant rate given by β and βS, which define the degradation rates of Notch1 ligands and receptors, and the free Notch1 intracellular domain (S), respectively. In our model (1), Notch1 is trans-activated by DLL4 (at rate kt) and JAG1 (at rate αkt) expressed in neighbouring cells, denoted by Dext (DLL4) and Jext (JAG1), and is cis-inhibited by DLL4 homodimers (at rate kci) co-expressed in the same cell. A comprehensive description of all parameters is detailed in Table 1.

Table 1. Description and baseline values of parameters used in simulations.

Par Description Values Units Source
bD Baseline production rate of DLL4 100 molec/hour According to [53]
bJ Baseline production rate of JAG1 100 molec/hour According to [53]
bN Baseline production rate of Notch receptor 500 molec/hour According to [53]
bR Baseline production rate of VEGFR2 800 molec/hour According to [53]
β Degradation rate of typical proteins 0.1 hour−1 Estimated from [54]
βS Degradation rate of free Notch Intracellular Domain and free VEGFR2 Intracellular Domain 0.5 hour−1 Estimated from [55]
kho Homodimerization rate of DLL4 1*10−4 molec−1*hour−1 [15]
khe Heterodimerization rate of DLL4 and JAG1 1*10−3 molec−1*hour−1 Assumed
kt Trans-activation rate 5*10−5 molec−1*hour−1 [15,28,29]
kci Cis-inhibition rate 6*10−4 molec−1*hour−1 [15]
kv VEGF-VEGFR2 binding rate 5*10−5 molec−1*hour−1 [28,29]
λ D Involved in regulating DLL4 production 10 dimensionless Estimated from [23]
λR Involved in regulating VEGFR2 production 0 dimensionless [28,29,41]
θD Involved in regulating DLL4 production 200 dimensionless [28,29,41]
θR Involved in regulating VEGFR2 production 30 dimensionless [28,29,41]
nD Involved in regulating DLL4 production 2 dimensionless [28,29,41]
nR Involved in regulating VEGFR2 production 2 dimensionless [28,29,41]
α The ratio of Notch1-JAG1 affinity to Notch1-DLL4 affinity in trans 1*10−4 dimensionless Assumed
Vext Concentrations of free VEGF at the growing front of angiogenic sprouting 2500 molec Assumed

Model (1) describes possible ligand and receptor interactions within the same cell and between cells. In common with previous publications [14,15,17,28,29], here we assumed that the functional protein-protein interactions proceed irreversibly. A novel component of this model is that it considers the experimentally observed DLL4-JAG1 hetero-dimerization and the different affinities for Notch1 of trans DLL4 and JAG1. Parameter α sets the ratio of Notch1-JAG1 affinity to Notch1-DLL4 affinity. Specifically, α=0 means that JAG1 does not mediate the trans-activation of Notch1, whereas α=1 means that JAG1 and DLL4 transactivate Notch1 with equal affinity. Consistent with the experimental findings, DLL4 homodimers, but DLL4-JAG1 heterodimers, mediate Notch1 receptor cis-inhibition.

Modelling DLL4/JAG1-Notch-VEGF signalling

Since angiogenic sprouting involves a tightly regulated interplay between Notch signalling and vascular endothelial growth factor (VEGF) receptor (VEGFR) signalling, based upon our new experimental results, we further elaborated our DLL4/JAG1-Notch signalling model (1) and propose a new theoretical model of DLL4/JAG1-Notch-VEGF signalling. In this model, free VEGF binds to VEGFR2 and stimulates intracellular VEGFR2 signalling, which upregulates the production of DLL4 in the same cell, as previously reported [22,23]. In turn, DLL4 stimulates Notch1 trans-activation and the intracellular Notch1 signalling downregulates the production of VEGFR2, a feedback mechanism which has been established experimentally [24,25]. With the addition of VEGFR2 signalling, the new model is presented mathematically as,

dDdt=H(V;θD,λD,nD)bD−βD−2khoD2−kheJD−ktNextD,dJdt=bJ−βJ−kheDJ−αktNextJ,dCdt=khoD2−βC−kciNC,dNdt=bN−βN−kciCN−ktDextN−αktJextN,dSdt=ktDextN+αktJextN−βSS,dRdt=H(S;θR,λR,nR)bR−βR−kvVextR,dVdt=kvVextR−βSV, (2)

where bR denotes the baseline production rate of VEGFR2 (R), and the free VEGF (Vext) induces intracellular VEGFR2 signalling (V) via binding to VEGFR2 (at rate kv). Other variables and parameters in model (2) represent the same biological terms described in model (1) and Table 1. The regulation of DLL4 production by VEGFR2 signalling and the regulation of VEGFR2 production by Notch signalling is given by a Hill function:

HX;θ,λ,n=λXn+θnXn+θn,

where the parameters θ, λ and n control the shape of this function. Specifically, λ>1 means upregulation and λ<1 means downregulation. In the absence of VEGFR2 signalling (i.e., bR=0), Eq. 2 reduces to Eq. 1.

Exploring the opposing effects of DLL4 and JAG1 on Notch signalling

We first investigated the effects of DLL4 and JAG1 on Notch1 signalling by analyzing model (1) theoretically. Let (D¯, J¯,C¯, N¯, S¯) be the positive steady state of model (1). According to the first two equations in the DLL4/JAG1-Notch signalling model (1), the steady-state levels of DLL4 and JAG1 satisfy the following equations:

D¯3+A1+B1D¯2+bJ−bD2kho+A1B1D¯−bD2khoB1=0, (3)
J¯3+bD−bJβ+αktNext+A2−β+αktNextB2J¯2+2bJB2−bJA2β+αktNextJ¯−bJ2B2β+αktNext=0, (4)

where

A1=β+ktNext2kho,    B1=β+αktNextkhe,    A2=β+ktNextkhe,    B2=2khokhe2.

Let

FD;bD,bJ=D3+A1+B1D2+bJ−bD2kho+A1B1D−bD2khoB1.

FD¯;bD,bJ=0, FDD¯;bD,bJ>0, thus the implicit function theorem implies that there is a smooth function h:R2→R such that D¯=hbD,bJ and

∂h∂bD=−FbDFD=D2khoFD>0,    ∂h∂bJ=−FbJFD=−D2khoFD<0 (5)

Inequalities (5) show that D¯ is an increasing function of bD and a decreasing function of bJ. Similarly, J¯ is a decreasing function of bD and an increasing function of bJ by analyzing Eq. (4). This means that an increasing production rate of JAG1 reduces the amount of available free DLL4 in the same cell, and an increasing production rate of DLL4 reduces the amount of available free JAG1 in the same cell.

In particular, if the parameter khe≫maxβ+ktNext,kho (i.e., the heterodimerization of DLL4 and JAG1 is very strong), Eqs. (3 and 4) can be approximated as:

D¯3+β+ktNext2khoD¯2+bJ−bD2khoD¯=0,J¯3+bD−bJβ+αktNextJ¯2=0.                     (6)

If bD>bJ (i.e., the production rate of DLL4 becomes larger than the production rate of JAG1 in the cell), this leads to:

D¯=β+ktNext4kho2+bD−bJ2kho−β+ktNext4kho,    J¯=0. (7)

Conversely, if bJ>bD (i.e., the production rate of JAG1 is greater than the production rate of DLL4 in the cell), this leads to:

D¯=0,    J¯=bJ−bDβ+αktNext. (8)

Thus, Eqs. (7 and 8) predict that, in the context of Notch1 receptor activity, the heterodimerization of DLL4 and JAG1 induces a mutual inactivation of the two ligands in the same cell (see S3 Fig). Which ligand predominates to control Notch signalling depends on their relative production rates in the cell.

We next tested if numerical simulations of the DLL4/JAG1-Notch signalling model (1) could recapitulate the observed opposing effects of DLL4 and JAG1 on Notch1 signalling (see Figs 2 and 3), and previously published data (see Fig 6 in [18]) similarly describing the different roles of DLL4 and JAG1 in the control of Notch1 signalling. We first considered the effects of DLL4 and JAG1 on Notch receptor cis-inhibition. Fig 4A schematically depicts the simulation setup where the level of DLL4 expressed at the cell surface of a sending cell is fixed and we simulate the dynamics of Notch, DLL4 and JAG1 in the receiving cell. This arrangement reproduces our experimental conditions (see Figs 2 and 3), and the pattern of ligand expression found in the sprouting front of the developing mouse retina [18]. In Fig 4B, we simulated the model to (near) steady-state levels of Notch activity (free Notch Intracellular domain) driven by a balance between the production rate of cis-DLL4 in the receiving cell (expressing Notch receptor), which is inhibitory, and fixed levels of trans-DLL4 in a sending cell, which is stimulatory. Increasing the production rate of cis-DLL4 resulted in an inhibition of Notch receptor activity (Fig 4B), which is consistent with our experimental data (see Fig 2). Next, in Fig 4C, we tested the effect of JAG1 on Notch receptor activity when the production rate of cis-DLL4 in the receiving cell is sufficient to inhibit Notch receptor activity. Clearly, model (1), which incorporates DLL4-JAG1 heterodimerization, but not a model lacking DLL4-JAG1 heterodimerization, faithfully reproduced our experimental observations (see Figs 2 and 3), which showed that JAG1 blocks DLL4-mediated Notch receptor cis-inhibition. Therefore, the model supports the view that DLL4-JAG1 heterodimerization is necessary to enable the opposing effects of DLL4 and JAG1 on Notch receptor signalling (see S4 and S5A–C Figs for additional simulations).

Fig 4. The potential mechanisms controlling the opposing effects of DLL4 and JAG1 on Notch1 receptor cis-inhibition and trans-activation.

Fig 4

(A) Diagrammatic representation of modelling simulation assays to explore the roles of DLL4 and JAG1 in Notch1 receptor cis-inhibition. (B) Notch activity in the receiving cell as a function of cis-DLL4 production rate. (C) Notch activity in the receiving cell as a function of cis-JAG1 production rate for a high level of cis-DLL4 (the maximum production rate shown in panel B). (D) Diagrammatic representation of modelling simulations assays to explore the roles of DLL4 and JAG1 in Notch1 receptor trans-activation. (E) Notch activity in the receiving cell as a function of trans-DLL4 production rate. (F) Notch activity in the receiving cell as a function of trans-JAG1 production rate for a high level of trans-DLL4 (the maximum production rate shown in panel E). In panel C and panel F, the blue lines represent the scenario with DLL4-JAG1 heterodimerization in the cells, the orange lines represent the scenario without DLL4-JAG1 heterodimerization, the solid lines represent that Notch1 has lower affinity for trans-JAG1 than trans-DLL4, and the dotted lines represent that Notch1 has the same affinity for trans-JAG1 and trans-DLL4.

Having established the requirement of DLL4-JAG1 heterodimerization for DLL4 and JAG1 control of Notch receptor cis-inhibition, we next addressed both the role of DLL4-JAG1 heterodimerization and also the different affinities for Notch1 of trans DLL4 and JAG1 in Notch receptor transactivation. Fig 4D schematically depicts the simulation setup wherein the level of Notch in the receiving cell is fixed and the sending cell could express both DLL4 and JAG1. Fig 4E shows that trans-DLL4, as expected (see Fig 1), efficiently stimulated Notch receptor signalling. Although, in vivo, the pattern of ligand expression suggests that leading edge tip cells express only high levels of DLL4 and lack JAG1 expression, neighbouring cells do express both DLL4 and JAG1 ligands [18], and previous reports have investigated co-expression of trans DLL4 and trans JAG1 in the sending cell [18]. In Fig 4F (also S4C–F and S5D–H Figs) we show that model (1), which includes the effects of DLL4-JAG1 heterodimerization (blue lines in Fig 4F), and relatively lower Notch1-JAG1 affinity compared to Notch1-DLL4 affinity (solid lines in Fig 4F), consistent with our experimental data (see Fig 1), faithfully reproduced the reported experimental data (see Fig 6 in [18]), which show that JAG1 limits DLL4-mediated Notch1 receptor trans-activation.

Collectively, our modelling results recapitulate the opposing effects of DLL4 and JAG1 on Notch1 signalling and highlights the importance of a novel mechanism whereby JAG1 directly blocks DLL4-mediated Notch cis-inhibition via DLL4-JAG1 heterodimerization, which could induce a mutual inactivation of DLL4 and JAG1 in cells (see S3 Fig), coupled to the relatively higher affinity for Notch1 of trans DLL4 compared to trans JAG1.

Recapitulating endothelial cell patterning in sprouting angiogenesis

The preceding analyses considered Notch1 signalling mechanisms controlled by DLL4-JAG1 heterodimer formation at the molecular and individual cell level. We next tested the validity of our model in the context of endothelial cell fate in sprouting angiogenesis. To mimic the in vivo microenvironment, we considered a gradient of VEGF across multiple connected cells yielding a front region with high VEGF concentrations (see Modelling methods), which delimited the site of tip/stalk cell formation through activation of the DLL4/JAG1-Notch-VEGF signalling network. In Fig 5A, we performed numerical simulations using different production rates of DLL4/JAG1 in the cells; and graphical depictions of the steady state levels of DLL4, JAG1, Notch activity and VEGFR2 activity in these interacting cells are shown. Our simulations show functional differentiation of endothelial cells into tip cells (characterized by high VEGFR2 activity) and stalk cells (with low VEGFR2 activity) over a broad range of DLL4/JAG1 production rates (see Figs 5A and S6). These results recapitulate the observed in vivo endothelial cell patterning in angiogenesis [18,26,31] where the tip cells and stalk cells are arranged alternately at the leading edge of the sprouting vasculature, which have also been successfully reproduced by other mathematical/computational models [26–29]. Furthermore, our model recapitulates the reported spatial expression of DLL4 and JAG1 in the endothelial cells [18], where the tip cells at the growing front have high levels of DLL4 (low levels of JAG1) whilst trailing cells express relatively lower levels of DLL4 (and higher levels of JAG1).

Fig 5. Recapitulating multicellular patterning (tip/stalk cell formation) at the early stage in sprouting angiogenesis.

Fig 5

(A and B) In silico replication of multicellular patterning mediated by DLL4, JAG1, Notch activity or VEGFR2 activity along the front edge of sprouting angiogenesis for different production rates of DLL4 and JAG1. The levels of VEGF decay exponentially from the top to the bottom (for a movie of the simulations, see S1 and S2 Videos). (Cand D) Notch activity in either of two interacting cells as a function of DLL4 production rate in cells. The simulations are based on the DLL4/JAG1-Notch signalling network (model (1), panel C) or DLL4/JAG1-Notch-VEGF signalling network (model (2), panel D) by assuming that there is no DLL4-JAG1 heterodimerization in the cells. The solid (black and red) lines represent stable states of VEGFR2 activity, and the dotted lines represent the unstable states of VEGFR2 activity.

In contrast to the simulations which include DLL4-JAG1 heterodimerization, the expected tip/stalk cell differentiation could not be reproduced in simulations without DLL4-JAG1 heterodimerization (see Fig 5B), although this model could recapitulate some features of the multicellular patterning observed in Fig 5A at a subset of DLL4/JAG1 production rates (e.g., see DLL4 = JAG1 = 25 and DLL4 = JAG1 = 400 in Fig 5B). To gain a deeper understanding of the necessary conditions for the differentiation of neighbouring cells into more specialized tip/stalk cells, from a modelling perspective, we present the steady state Notch activity as a function of DLL4 production rate by simulating two interacting cells in the absence of DLL4-JAG1 heterodimerization (Fig 5C, model (1); Fig 5D, model (2)). Comparing Fig 5C and 5D, if the intracellular Notch activity was within a defined range (marked by green shading in Fig 5C), the DLL4-Notch-VEGF signalling network would induce multiple stable states of proteins in the cells (the solid red lines in Fig 5D), which corresponds to the emergence of the different cell fates of the interacting cells (see DLL4 = JAG1 = 25 and DLL4 = JAG1 = 400 in Fig 5B). In Figs 2–4, we have shown that the heterodimerization of DLL4 and JAG1 could be a central mechanism in the control of Notch1 signalling. Thus, these simulations suggest that the DLL4-JAG1 heterodimerization could be critical for tip/stalk cell formation during sprouting angiogenesis within specified thresholds of Notch ligand expression.

Modelling the molecular basis of the opposing effects of DLL4 and JAG1 on endothelial cell fate in sprouting angiogenesis

In the simulations of tip/stalk cell patterning in sprouting angiogenesis, our DLL4/JAG1-Notch-VEGF signalling model (2) recapitulates the reported finding [18] that a tip cell (characterized by high VEGFR2 activity) expresses high levels of DLL4 and lacks JAG1 at the growing front (see Fig 5A). We next explored the mechanisms by which differential DLL4 and JAG1 production rates could underlie their opposing effects on sprouting angiogenesis (see S7 Fig A for a schematic depiction of this process). In Fig 6A and 6B, we simulated a line of interacting cells, representing the growing front of sprouting angiogenesis, for varying production rates of DLL4 and JAG1 in the cells, respectively. Because tip cells direct the emergence of new sprouts during sprouting angiogenesis [1], the effects of Notch ligands (DLL4 and JAG1) on sprouting angiogenesis could be characterized by their effects on tip cell number. According to experimental estimates (see Parameters in the Methods section), when the production rates of DLL4 and JAG1 correspond to the wild-type scenario, in response to increased VEGFR activity, tip cells express high levels of DLL4 and lack JAG1 (WT in Fig 6A and 6B). For low production rates of DLL4 (DLL4+/− in Fig 6A) or high production rates of JAG1 (JAG1iGOF in Fig 6B), the modelling predicts that endothelial cells would preferentially adopt a tip cell fate (characterized by high VEGFR2 activity) and thus could be expected to form an excessive number of sprouts. For high production rates of DLL4 ( in Fig 6A) or low production rates of JAG1 (JAG1+/− in Fig 6B), the modelling predicts that the endothelial cells would preferentially adopt a stalk cell fate (characterized by low VEGFR2 activity) and thus could be expected to develop a sparse vascular network. These simulations clearly demonstrate the opposing effects of DLL4 and JAG1 on endothelial cell fate, and the biological implications are consistent with experimental observations in sprouting angiogenesis [18,24,30–32]. To decipher the molecular basis of the opposing effects of DLL4 and JAG1 on endothelial cell fate, we presented the steady-state levels of VEGFR2 activity in two interacting cells as a function of DLL4 production rates for different production rates of JAG1 in the presence (Fig 6C) or absence (S7B Fig) of DLL4-JAG1 heterodimerization. The numerical analysis in Fig 6C and S7B Fig suggests that the opposing effects of DLL4 and JAG1 on endothelial cell fate is highly dependent on DLL4-JAG1 heterodimerization because the bifurcation diagram of VEGFR2 activity would be independent of JAG1 production rate in the cells if there was no DLL4-JAG1 heterodimerization (see S7B Fig).

Fig 6. Recapitulating the opposing effects of DLL4 and JAG1 on endothelial cell fate in sprouting angiogenesis.

Fig 6

(A and B) Numerical simulations of DLL4 levels, JAG1 levels, Notch activity and VEGFR2 activity in a line of interacting cells. The production rates of DLL4 and JAG1 increase from the bottom to the top. A warmer color means higher levels of corresponding proteins in the cells. According to the production rates of DLL4 and JAG1, we divided the simulations in panels A and B into mutant groups (DLL4+/−or JAG1+/−), wild-type groups (WT), and overexpression groups (DLL4iGOF or JAG1iGOF). (C) Bifurcation diagram of VEGFR2 activity in either of two interacting cells driven by DLL4 production rate in cells for different JAG1 production rate. The simulations are based on the DLL4/JAG1-Notch-VEGF signalling model (2) with DLL4-JAG1 heterodimerization.

Recently, Tiemeijer et al. [33] utilized an elegant combination of bioengineering and a novel endothelial cell culture assay to study endothelial sprouting controlled by defined patterns of JAG1 and DLL4. They showed that defined stripes of functional DLL4 protein guide the location and direction of angiogenic sprouts by specifically excluding spouting within the stripes of DLL4, while equivalent stripes of functional JAG1 protein do not exert such effects, which is depicted schematically in Fig 7A. Fig 7B and 7C shows that our DLL4/JAG1-Notch-VEGF signalling model (2) could recapitulate these effects. We simulated a line of interacting cells exposed to increasing concentrations of either trans-JAG1 (Fig 7B) or trans-DLL4 (Fig 7C). In agreement with the findings of Tiemeijer et al. [33], increasing levels of trans-DLL4, but not trans-JAG1, spatially restricted endothelial cell patterning. In Fig 7D and 7E, we present the steady-state levels of VEGFR2 activity in two interacting cells driven by different levels of trans-JAG1 and trans-DLL4. Clearly, high levels of trans-DLL4 lead to reduced VEGFR2 activity in the cells (Fig 7E), while changes in trans-JAG1 levels had little effect on VEGFR2 activity (Fig 7D). Consistent with our experimental results (Fig 1) and previous reports [33], the different effects of DLL4 and JAG1 in controlling sprouting angiogenesis is also highly dependent on the different affinities for Notch1 of trans DLL4 and JAG1 (see Fig 7F).

Fig 7. Recapitulating the spatial control of DLL4 and JAG1 to sprouting angiogenesis.

Fig 7

(A) Diagrammatic representation of the effect of trans-JAG1 and trans-DLL4 on endothelial cell behaviours. DLL4 elicits spatial control in sprouting angiogenesis whereas JAG1 has no effect on it. (B and C) Numerical simulations of VEGFR2 activity in a line of interacting cells exposed to different levels of trans-JAG1 (B) or trans-DLL4 (C) engineered in two (shaded) stripes. The level of trans-ligands in the (shaded) stripes increases linearly from the bottom to the top. (D and E) Bifurcation diagram of VEGFR2 activity in either of two interacting cells driven by the level of trans-JAG1 (panel D) or trans-DLL4 (panel E) exposed to the cells. Here the affinity of Notch1 for trans-JAG1 is low (α=0). (F) Phase-diagram (two parameters bifurcation) of cell fate of interacting cells driven by the trans-JAG1 level and JAG1-Notch affinity. Patterning means that the interacting cells would show alternating cell fate marked by the proteins in the cells (as shown in panels B and C).

Collectively, these data demonstrate that our model recapitulates endothelial cell fate driven by the Notch ligands, DLL4 and JAG1, in sprouting angiogenesis, and underscore the importance of DLL4-JAG1 heterodimerization and the different affinities for Notch1 of trans DLL4 and JAG1 in this process.

Discussion

Since the discovery of the Notch receptor in the second decade of the last century, both pioneering work in in vivo model systems, as well as cell and biochemical analyses, have provided a detailed, albeit incomplete, picture of its essential roles in animal development and the basic molecular underpinnings of its function. In general outline, Notch receptors can interact with their ligands within the same cell or between cells and the net effect of these interactions determines the level of Notch receptor activation. Related to this, a currently unanswered question of central importance is how different Notch receptor and ligand combinations control this process to produce its observed effects. Given the wide range of distinct physiological phenomena which are governed by this relatively simple receptor-ligand network (see [1–7]), multiple additional regulatory mechanisms must operate to enable the broad repertoire of possible responses, including biomechanical forces [4,8], post-translational modifications of both receptors and ligands [7], asymmetric cell divisions and processes which promote and control action-at-a-distance Notch signalling activities [34].

In this study, we have used simple experimental approaches coupled to mathematical modelling to address this question, specifically by considering how the JAG1 and DLL4 ligands differentially control Notch1 receptor activation, a question of fundamental relevance in light of the well-established evidence for the opposing effects of DLL4 and JAG1, which together control angiogenic sprouting [18,19]. Consistent with previous studies [35–37], our data show that, by comparison with JAG1, DLL4 has a significantly greater capacity to stimulate trans-activation of Notch1 receptor signalling (see Fig 1). We further show that DLL4, but not JAG1, efficiently mediates Notch1 receptor cis inhibition. In addition to the significant differences in the magnitude of Notch1 transactivation and cis inhibition elicited by each ligand (Fig 2), we have uncovered the previously overlooked phenomenon of ligand heterodimerization (Fig 3). Specifically, we show that a JAG1/DLL4 heteromeric complex blocks DLL4-dependent Notch receptor cis inhibition thereby allowing receptor transactivation, which is stimulated by ligands expressed by neighbouring cells. In this view, JAG1 can directly, and precisely, fine-tune DLL4 transactivation of Notch1, which is determined by the relative expression levels of each ligand. Given the evidence that DLL4 homodimerization could be necessary for cis inhibition [15], one plausible mechanism to account for our findings is that JAG1 monomers compete with DLL4 for binding to other DLL4 monomers. In this respect, it is noteworthy that JAG1 appears to display a higher affinity for DLL4 than DLL4 has for itself (see S8 Fig). Our data further suggest that the absence of a VWFC domain in JAG1, an oligomerization domain which is expressed by the highly related JAG2 ligand, has enabled this mechanism by precluding the formation of JAG1 homodimers (in contrast to all other Notch ligands (see Fig 2; [15]). It is compelling that there are parallels between this (presumably relatively ancient) mechanism and a remarkable recent evolutionary innovation which has been proposed to explain, at molecular resolution, the dramatic expansion in size of the cortical region of the human brain, whereby small ligand-like Notch2 receptor paralogues enable Notch receptor activation by directly binding to, and potentially blocking, DLL1-dependent receptor cis inhibition [38].

Significant advances in our understanding of Notch signalling have emerged, and continue to emerge, through use of powerful mathematical approaches coupled with in silico modelling of the biological consequences of the molecular and cellular processes involved in this pathway [14–16,25–29,39–43]. Several existing models have addressed the distinct roles of JAG1 and DLL4 in angiogenic patterning [33,41]. Recently, using a combined experimental and computational approach, Tiemeijer et al. [33] showed that spatial and temporal differences in the control of Notch activity by DLL4 and JAG1 underlie endothelial sprouting. Boareto et al. [41] undertook a different approach to model the asymmetric effects of DLL4 and JAG1 on endothelial cell fate in which the opposing effects of DLL4 expression and JAG1 expression on Notch signalling suggest that high production levels of DLL4 establish the tip-stalk phenotype in interacting cells while high production rates of JAG1 destabilizes the tip and stalk cell fates and can give rise to a hybrid tip/stalk phenotype.

Here, we have proposed a new mathematical model, which is a refinement of our previously described general model [15], which takes into account our new experimental insights into DLL4 and JAG1 control of Notch1 receptor signalling. It should be stated that we cannot rule out that ligand monomers and dimers might dynamically associate and dissociate during Notch signalling, but most mathematical models [14,15,17,28,29], including the model we proposed here, do not take into account the possible reversibility of these interactions. However, we can show that if ligand dimerization, as well as ligand/receptor cis- and trans-binding, is reversible, the conclusions of this paper will still hold (see Modelling methods). Our model faithfully recapitulates both published data (see Fig 4D–F) and the experimental findings of the study presented here (see Fig 4A–C). Numerical simulations and bifurcation analysis of the model predict that the high affinity of DLL4, and low affinity of JAG1, for Notch1 is critical for recapitulating the distinct responses of endothelial cells to trans DLL4 and JAG1 (Fig 7A–F), in agreement with other models [16]. Importantly, our model underscores the role of DLL4-JAG1 heterodimerization in determining the opposing effects of DLL4 and JAG1 on angiogenesis, specifically, the specialization of endothelial cells into leading edge tip cells and trailing stalk cells, which is necessary for vessel sprouting (Figs 5 and 6).

In this model, we have focussed on endothelial cells and the two principal signalling pathways, Notch1 and VEGFR signalling, which mutually guide endothelial cell fate. A future elaboration of this model could incorporate other Notch receptor members, and other cytokine/growth factor signal transduction pathways (e.g., the inflammatory cytokine, tumour necrosis factor-α (TNF-α) was reported to up-regulate JAG1, but reduce DLL4 transcript levels in endothelial cells [18]. It could also take account of other cell types and signalling modules, including the Notch3 signal transduction pathway in vascular smooth cells [19]. Related to that, whilst negative feedback mechanisms have been shown to be critical for angiogenesis, specifically by linking VEGFR signalling to Notch via VEGF stimulation of DLL4 expression, and Notch-mediated suppression of VEGFR expression, Page et al. [44] delineated a positive feedback mechanism, which could underpin the timing and the scale of angiogenesis. Moreover, during Drosophila development, there is evidence that Delta ligand in the sending cell activates Notch in the receiving cell which suppresses Delta expression in the receiving cell (see [34]). In the context of our new model, by considering these facets of Notch signalling and endothelial sprouting, we could get not only deeper insights into normal developmental sprouting angiogenesis but also into other physiological processes, such as wound healing [19], and the pathological angiogenesis unique to solid tumours, and chronic inflammatory and autoimmune diseases [45,46]. Indeed, regarding other Notch receptor family members, our evidence that ligand heterodimerization could play a role in Notch signalling has potentially important implications for our understanding of the control of this central signal transduction pathway more generally. For example, heteromeric Notch ligand complex formation might serve to increase the number of possible Notch receptor signalling outputs. Certainly, our reported effects are not limited to Notch1 signalling alone. In comparable assays of receptor transactivation and cis inhibition, JAG1/DLL4 heterodimers similarly controlled both Notch2 and Notch3 signalling activity (see S9 Fig). Since all Notch ligands share a common overall architecture, it could be of interest to investigate if other Notch ligands can form heteromeric complexes, and to decipher the possible biological consequences of these interactions. Additional mechanisms could also contribute to the overall regulation of the Notch network including signalling initiated by processing of the ligand intracellular domains [47], and a possible role for Notch receptor oligomerization/dimerization, which would add an additional layer of complexity to the system, though the precise molecular details of this remain elusive [48].

As well as angiogenesis, our results may shed light on our understanding of the patterning of other tissues. A well-characterized, ancient example is dorsal/ventral (D/V) boundary formation in Drosophila wing disc development. Dorsal cells express Notch, Delta and Serrate, ventral cells express Notch and Delta only, moreover, Delta expression is especially high at the D/V boundary [49–52], an arrangement not dissimilar to the expression patterns of DLL4 and JAG1 found in tip and stalk cells in the angiogenic front of the developing mouse retina [18]. At the early stage of dorsal/ventral boundary formation, Serrate in dorsal cells is believed to transactivate Notch in ventral cells and Delta in ventral cells transactivates Notch in dorsal cells, thereby delimiting a sharp stripe of Notch activation at the dorsal/ventral interface. Currently, it is not fully understood how such a defined pattern of Notch activity is generated and sustained, and a possible contributing factor could be that the relative production rates of Serrate and Delta in the two cell types establishes signalling thresholds, comparable to those observed in adjacent endothelial tip and stalk cells, which enables a heteromeric ligand complex to spatially and temporally restrict Notch receptor activation.

In summary, we have presented a model of Notch signalling which incorporates the novel finding that JAG1 directly antagonizes the function of DLL4 through the formation of heteromeric DLL4-JAG1 complexes, which could underlie the observed opposing effects of JAG1 and DLL4 in sprouting angiogenesis. By integrating DLL4 and JAG1 dynamics, and DLL4/JAG1 dimerization, into our previous theoretical understanding of Notch signalling, a new mathematical model for tip endothelial cell selection in angiogenesis is proposed which successfully recapitulates the biological observations that JAG1 and DLL4 play distinct roles in angiogenesis. Bifurcation analysis of the mathematical model predicts that DLL4-JAG1 dimerization and their respective asymmetric affinities for Notch are critical for explaining the opposing effects of DLL4 and JAG1 on angiogenesis. Future work will determine if our findings may have broader relevance to other normal and pathological tissue processes.

Materials and methods

Modelling methods

In this paper, we present a mathematical model (1) of Notch1 signalling, which does not consider the possible reversibility of ligand and receptor interactions. In contrast to previous models [14,15], DLL4-JAG1 heterodimerization is a newly introduced protein-protein interaction. Reversible DLL4-JAG1 heterodimerization is represented mathematically by:

D+J↔association/dissociationDJ→degradation∅.

If the DLL4-JAG1 complexes DJ can dissociate, the dynamics of DLL4 levels and JAG1 levels can be expressed as:

dDdt=bD−βD−2khoD2−k+DJ−k−DJ−ktNextD,dJdt=bJ−βJ−k+DJ−k−DJ−αktNextJ,                  dDJdt=k+DJ−k−DJ−βDJ,                                  (9)

where k+ and k− represent the association/dissociation rates of DLL4-JAG1 complexes DJ. At the positive steady state (D¯, J¯,DJ¯) of Eq. (9), we have:

bD−βD¯−2khoD¯2−k+D¯J¯−k−DJ¯−ktNextD¯=0,bJ−βJ¯−k+D¯J¯−k−DJ¯−αktNextJ¯=0,               k+D¯J¯−k−DJ¯−βDJ¯=0.                                          (10)

Let khe=βk+/β+k−, the first two equations in Eq. (10) can be rewritten as:

bD−βD¯−2khoD¯2−kheD¯J¯−ktNextD¯=0,bJ−βJ¯−kheD¯J¯−αktNextJ¯=0,                 (11)

Comparing Eq. (11) with the first two equations of model (1), it can be seen that introducing DLL4-JAG1 heterodimerization reversibility does not change the results of this paper. More generally, if the cis- and trans- binding of Notch ligands and receptors is also assumed to be reversible, the equilibrium of an extended model does not differ substantially from the current, widely accepted, simplified model [14]. In S3 Fig, we also show that allowing the disassociation of DLL4 homodimers does not change the predicted mutual inactivation between DLL4 and JAG1 in the same cell.

Parameters.

The values of parameters in our model are determined based on previous works and our new data. Published data have suggested that Notch-related protein levels vary by up to a few hundred ng/ml, or a few thousand molecules per cell [53], thus the production rates of Notch ligands, Notch receptor, VEGFR2 are assumed to produce corresponding amounts of protein in the cell (see Table 1). The degradation rate of proteins is set β=0.1/hour, equivalent to a half-life of about 7 hours [54]. The degradation of free Notch Intracellular Domain (S) and free VEGFR2 Intracellular Domain is assumed to beβS=0.5/hour because the signal in Notch signalling and VEGFR2 signalling decays rapidly [55]. In S5 Fig, we tested different degradation rates of proteins, and the variation in degradation rates did not affect our results. We assume that the DLL4-JAG1 heterodimerization rate is khe=10−3/molec*hour, which is bigger than the DLL4-DLL4 homodimerization rate kho=10−4/molec*hour [15] because our new data imply that DLL4-JAG1 affinity could be bigger than DLL4-DLL4 affinity (see S8 Fig). The trans-activation rate, cis-inhibition rate and VEGF-VEGFR2 binding rate were derived from previous studies [15,28,29], the authors estimated their parameters by referring to relevant experimental reports. The fold change of VEGFR2 activity-dependent up-regulation for DLL4 expression is close to 10 [23], and the fold change of Notch activity-dependent regulation for VEGFR2 expression is assumed to be 0 [28,41]. The values of other parameters related to VEGFR2/Notch activity-dependent regulation for DLL4 and VEGFR2 also come from previous modelling studies [28,29,41].

Numerical simulations.

Unless otherwise specified, the numerical simulations were performed on MATLAB R2021a using the parameter values in Table 1. The fourth-order Runge–Kutta methods were used in all scenarios.

In the simulations, the levels of trans-ligandsDext, Jext are context-dependent. For the single cell in S3 Fig, Dext=Jext=0; for multiple interacting cells (including two cells), the level of trans-ligand is the average of ligands in neighbouring cells (Figs 4, 5, 6 and S5); for multiple interacting cells exposed to fixed level of trans-ligands, the level of trans-ligand is the average level of ligands in neighbouring cells plus the level of external ligands which varies from 0 to 200 (Fig 7).

In Figs 5A, 5B and S6, each cell is represented as a regular hexagon with side length 1. The concentrations of VEGF decay exponentially from the growing front y0to trailing areas, according to Vy=Vext/expay−y0, where y is the vertical coordinate of each cell center. In particular, y=y0 represents the vertical coordinate of the center of the first row of cells. Parameter acontrols the sharpness of VEGF concentrations (a=1 in Fig 5). The initial value of these simulations is random, and the boundary value uses the Dirichlet boundary 0.

In Figs 6 and 7, the line of cells represents the growing front, thus the concentration of VEGF is fixed at Vext.

Numerical bifurcation analysis.

In Figs 5D, 6C and 7D–F, the numerical bifurcation analysis for two cell system was performed by using the package MatCont [56]. The black solid lines represent the stable homogeneous steady-states, the black dotted lines represent the unstable homogeneous steady-states, the red solid lines represent the stable heterogeneous steady-states, and the red dotted lines represent the unstable heterogeneous steady-states.

Experimental methods

Cell culture, biochemistry and molecular biology.

Human embryonic kidney 293T cells were cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco). Cell lines were typed using short tandem repeat analysis of the DNA and all cell lines were checked for mycoplasma with the MycoAlert kit (Lonza). Transfections, lentivirus production and cell infections, Western blotting and co-immunoprecipitations have been described previously [57,58]. All lysis buffers contained a cocktail of protease inhibitors (phenylmethylsulfonyl fluoride, trypsin inhibitor, pepstatin A, leupeptin, aprotinin).

Recombinant protein production/ in vitro protein:protein interaction.

Domains for recombinant protein production were cloned into the pET 28a vector in-frame to an N-terminal 6x HIS epitope. His epitope–tagged proteins were manufactured in Escherichia coli BL21(DE3). Following sonication (Misonix Sonicator 3000) in 3 mls ice-cold buffer/ 50 ml bacterial culture (150 mM NaCl, 2.7 mM KCl, Na2HPO4, KH2PO4, 20 mM imidazole, 10 mM β-mercaptoethanol), proteins were purified onto 50 ul of Nickel- agarose beads (Qiagen) by 3 hours rolling at 4C. Beads were washed in 10 x 1 ml of the same buffer. Protein yields were determined by Bradford assay (Bio-Rad) and relative protein integrity and purity was determined by SDS-PAGE and Colloidal Blue staining (Invitrogen). Purified recombinant protein was incubated with 10 ul nickel beads in 1 ml of buffer for 2 hours at 4oC with in vitro translated DLL4 proteins made using the TNT-coupled reticulocyte in vitro translation system (Promega). Beads were washed x10 with 1 ml of buffer. Proteins were separated by SDS-PAGE and associated proteins were detected by Western blot.

Plasmid construction.

Unless otherwise stated, all cDNAs were fused in-frame with a C-terminal FLAG, HIS or HA epitope tag and were cloned into the pLV lentiviral vector and pCS2 expression plasmid. Expression of these proteins was determined using antibodies directed against either the coding region of the protein or the epitope tag. Mutants were generated by site-directed mutagenesis using Phusion High-Fidelity DNA polymerase (Thermo fisher). All constructs were verified by Sanger sequencing (Macrogen).

Luciferase reporter.

Stable cell lines expressing epitope-tagged ligands and receptors were established via infection of cells with lentiviruses harbouring the appropriate ligand/receptor cDNA followed by selection with the encoded antibiotic (puromycin or neomycin). For ‘cis inhibition’ assays, cells co-expressing ligand, receptor and reporter were co-cultured with cells expressing ligand alone (to enable transactivation). Comparable results were obtained for co-culture ratios of 1:1, 1:2, 1:4. For transactivation analyses, cells stably expressing ligand alone were co-cultured with cells expressing receptor and reporter (1:1 ratio) at a confluency of approximately 90% (0.45 x 106 cells/well), to ensure cells were touching to enable suitable transactivation. For each experiment, cells were seeded in triplicate in 12-well plates. The Notch luciferase reporter harboured 10x RBPJ consensus binding sites, and was co-transfected with Renilla luciferase control plasmid. Transfection efficiencies (routinely >90%) were determined through visualization of co-transfected plasmid encoding the Tomato fluorescence reporter. Cells were lysed 36 hours post-plating, and luciferase activity was measured using a luciferase assay substrate (Promega). Luciferase activity was normalized by measuring Renilla luciferase activity (Promega). Receptor and ligand protein levels were determined by Western blotting (see S10 Fig). Experiments were performed three times. The statistical hypothesis tests in this study were performed using Student’s t-test. We defined P<0.0001 as a highly significant difference (**), P<0.001 as a significant difference (*), and P≥0.001 as not significant (n.s.).

Ligand/receptor binding assay.

Confluent 10 cm dishes of 293T cells stably expressing HA-epitope tagged Notch receptors were washed with ice-cold PBS/BSA (1 mg/ml). Cells were stimulated with 50 μL of ligand (0.5 mg/ml) in the presence of 1.5 mls of PBS/BSA (1 mg/ml) for 1 hour, with gently shaking, at 4oC. Cells were washed once with PBS. Cells were incubated with crosslinkers in the presence of 2 mls of ice-cold PBS for 15 minutes, with gently shaking at 4oC: 5 μL/ml DSS (54 mML) and 5 μL/ml BS3 (13 mM). Cells were washed once with ice-cold detachment buffer (10mM Tris-HCl pH 7.4, 1mM EDTA pH 7.4, 10% glycerol), scraped off the plates in 1 ml of detachment buffer and transferred to Eppendorf tubes. Cell pellets were lysed in 1 ml of solubilization buffer (125mM NaCl, 10mM Tris-HCl pH 7.4, 1mM EDTA pH 7.4, 1% Triton X-100) on ice for 30 minutes and centrifuged at 13k rpm for 10 minutes. Supernatants were incubated with HA antibody (Covance catalog# MMS-101P, 16B12) overnight at 4oC. 50 μL of washed (4x) protein A/G beads (50% solution) were added and samples were incubated for 45 minutes at 4oC. The beads were washed four times with solubilization buffer. 50 μL of sample buffer was added and samples were boiled for 5–10 mins prior to gel electrophoresis.

Antibodies, proteins and drugs.

Antibodies were obtained from the following sources: FLAG mouse M2 monoclonal (Sigma); anti-HA.11 mouse monoclonal (Covance); anti-HA rabbit polyclonal (Abcam); anti-FLAG rabbit (Sigma); anti-γ-tubulin (Sigma); anti-His (Sigma). Nickel-NTA agarose was purchased from Qiagen. Recombinant human ligands were obtained from: JAG1 protein (Acrobiosystems, Cat. No: JA1-H52H9); DLL4 protein (Acrobiosystems, Cat. No: DL4-H5227); DLL4 protein (AbCam, Cat. No: ab219667).

Supporting information

S1 Fig. JAG1 efficiently binds to Notch1 in cis.

293T cells were co-transfected with the indicated combinations of HA epitope-tagged JAG1 and HIS6 epitope-tagged Notch. Ligands were resolved using an anti-HA antibody and ligand-receptor complexes were determined by Western blotting with the indicated antibodies.

(EPS)

S2 Fig. Cis DLL4-JAG1 heterodimerization enables efficient trans DLL4-dependent cleavage of Notch.

293T cells expressing, in cis, the indicated combinations of HA epitope-tagged Notch, FLAG epitope-tagged DLL4 or HIS6 epitope-tagged JAG1, were cultured in the presence or absence of recombinant (trans) DLL4 for the indicated time-course. Cells were cultured in 6 cm dishes and lysed directly in denaturing Laemmli buffer to enable detection of processed Notch. Notch receptor cleavage was monitored by Western blotting with an anti-HA antibody. Expression levels of DLL4, JAG and the housekeeping gene, Vinculin, were determined by Western blotting with the indicated antibodies. DLL4-(EGF7) lacks the EGF-like repeat 7.

(EPS)

pcbi.1012825.s002.eps (1.4MB, eps)
S3 Fig. Mutual inactivation of DLL4 and JAG1 in the same cell.

(A) The simulation is based on the DLL4/JAG1-Notch signalling model (1) with strong DLL4-JAG1 heterodimerization (khe=0.1). The production rate of DLL4 in the cell is fixed at bD=100. (B) The simulation was performed under the same conditions, but the dissociation of the DLL4 homodimer was taken into account.

(TIFF)

pcbi.1012825.s003.tiff (3.1MB, tiff)
S4 Fig. Two-dimensional simulations of the results presented in.

Fig 4. The relative levels of Notch activity (NICD) in response to different production rates of: (A and B) cis-DLL4 (bD)/JAG1 (bJ), and (C–F) trans-DLL4 (bD)/JAG1 (bJ), across the two-dimensional plane (bD, bJ).

(TIFF)

pcbi.1012825.s004.tiff (16.6MB, tiff)
S5 Fig. Extended simulations of the results presented in.

Fig 4. (A–C) Notch activity in the receiving cell as a function of cis-ligand production rates. (D–H) Notch activity in the receiving cell as a function of trans-ligand production rates. The degradation rates of ligand monomer, ligand dimer and Notch receptor are independently assumed to be: 0.05/h (a half-life of about 14 hours), 0.15/h (a half-life of about 5 hours), or 0.25/h (a half-life of about 3 hours).

(TIFF)

pcbi.1012825.s005.tiff (9.4MB, tiff)
S6 Fig. Extended simulations of the cellular patterning described in Fig 5A.

The simulations were performed with a shallower VEGF gradient. The VEGF concentration was set according to: (A) Vy=Vext/exp2y−y0; (B) Vy=Vext/exp5y−y0; C) Vy=Vext/exp35y−y0. See Numerical simulations (Methods) for simulation information.

(TIF)

pcbi.1012825.s006.tif (7.4MB, tif)
S7 Fig. (A) Diagrammatic representation of the effects of JAG1 and DLL4 on endothelial cell behaviours.

DLL4 inhibits sprouting angiogenesis whereas JAG1 promotes it. (B) Bifurcation diagram of VEGFR2 activity in either of two interacting cells driven by DLL4 production rate in the cells. The simulations are based on the DLL4/JAG1-Notch-VEGF signalling model (2) by assuming that there is no DLL4-JAG1 heterodimerization in the cells. In this scenario, the variation of JAG1 production rate does not affect the bifurcation diagram driven by DLL4 production rate.

(TIFF)

pcbi.1012825.s007.tiff (6.8MB, tiff)
S8 Fig. Differential affinities of JAG1-DLL4 and DLL4-DLL4 interactions.

(A) HIS epitope tagged DLL4 immunopurified from 293T cells using nickel-NTA agarose was incubated with the indicated combinations of (cell-expressed) HA epitope tagged DLL4 and JAG1. Protein Interactions were determined by Western blotting with the indicated antibodies. (B) Quantification of the bands shown in (A).

(EPS)

pcbi.1012825.s008.eps (2.8MB, eps)
S9 Fig. A DLL4-JAG1 heterodimer blocks DLL4-mediated Notch2 and Notch3 receptor cis inhibition and enables efficient Notch2 and Notch3 receptor transactivation.

(A) Schematic representation of luciferase reporter assays performed as described in the Methods. (B) 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch2 receptor and ligand constructs (stalk cells) were co-cultured with cells stably expressing DLL4 (tip cells) to enable transactivation. DLL4-Δ(EGF7) and DLL4-Δ(EGF8) lack the EGF-like repeat 7 and the EGF-like repeat 8 (see Fig 3C), respectively. For each analysis, reporter activity was normalized using Renilla luciferase. Levels of ectopically expressed proteins were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown. (C) 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch3 receptor and ligand constructs (stalk cells) were co-cultured with cells stably expressing DLL4 (tip cells) to enable transactivation. DLL4-Δ(EGF7) and DLL4-Δ(EGF8) lack the EGF-like repeat 7 and the EGF-like repeat 8 (see Fig 3C), respectively. For each analysis, reporter activity was normalized using Renilla luciferase. Levels of ectopically expressed proteins were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown.

(EPS)

pcbi.1012825.s009.eps (3.2MB, eps)
S10 Fig. Protein levels of Notch receptors and ligands were determined by Western blotting of lysates corresponding to the following luciferase reporter assays: (A) Fig 1A.

(B) Fig 2A. (C) Fig 2E. (D) Fig 3B. (E) Fig 3E.

(EPS)

pcbi.1012825.s010.eps (9.5MB, eps)
S1 Video. Multicellular simulations of tip/stalk cell patterning in sprouting angiogenesis.

This video corresponds to Fig 5A with DLL4-JAG1 heterodimerization.

(GIF)

pcbi.1012825.s011.gif (6.8MB, gif)
S2 Video. Multicellular simulations of tip/stalk cell patterning in sprouting angiogenesis.

This video corresponds to Fig 5B without DLL4-JAG1 heterodimerization.

(GIF)

Acknowledgments

We are very grateful to Maarten van Dinther and Lin-Ting Wu for excellent technical assistance with the experimental work. We thank members of the Department of Cell & Chemical Biology at the LUMC for helpful discussions and support, in particular, Prof. Peter ten Dijke, Dr Manuel Goncalves and Shaima Abdalla.

Data Availability

All relevant data are within the manuscript and its Supporting Information files. Code running on MATLAB R2021a can be accessed via: https://github.com/DaipengChen/Notch-Angiogenesis.

Funding Statement

This work was supported by the Dutch Cancer Society (30861) to DAB, the Nederlandse Organisatie voor Wetenschappelijk Onderzoek grant NWO/ENW-VICI 865.17.004 to RMHM, the Cancer Genomics Centre Netherlands (CGC.NL) to XL. DC and HW were recipients of Chinese Scholarship Council (CSC) funding as part of the CSC Joint PhD Program on Artificial Intelligence and Bioscience between Leiden University and Xi’an Jiaotong University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and disease. Physiol Rev. 2017;97(4):1235–94. doi: 10.1152/physrev.00005.2017 [DOI] [PubMed] [Google Scholar]
  • 2.Gazave E, Lapébie P, Richards GS, Brunet F, Ereskovsky AV, Degnan BM, et al. Origin and evolution of the Notch signalling pathway: an overview from eukaryotic genomes. BMC Evol Biol. 2009;9:249. doi: 10.1186/1471-2148-9-249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216–33. doi: 10.1016/j.cell.2009.03.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Henrique D, Schweisguth F. Mechanisms of Notch signaling: a simple logic deployed in time and space. Development. 2019;146(3):dev172148. doi: 10.1242/dev.172148 [DOI] [PubMed] [Google Scholar]
  • 5.Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol. 2016;17(11):722–35. doi: 10.1038/nrm.2016.94 [DOI] [PubMed] [Google Scholar]
  • 6.Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95. doi: 10.1038/s41392-022-00934-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Meng Y, Bo Z, Feng X, Yang X, Handford PA. The Notch signaling pathway: mechanistic insights in health and disease. Engineering. 2024;34:212–32. doi: 10.1016/j.eng.2023.11.011 [DOI] [Google Scholar]
  • 8.Sprinzak D, Blacklow SC. Biophysics of Notch signaling. Annu Rev Biophys. 2021;50:157–89. doi: 10.1146/annurev-biophys-101920-082204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002;3(9):673–84. doi: 10.1038/nrm910 [DOI] [PubMed] [Google Scholar]
  • 10.Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell. 2000;5(2):197–206. doi: 10.1016/s1097-2765(00)80416-5 [DOI] [PubMed] [Google Scholar]
  • 11.Kitagawa M. Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators. J Biochem. 2016;159(3):287–94. [DOI] [PubMed] [Google Scholar]
  • 12.Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet. 2012;13(9):654–66. doi: 10.1038/nrg3272 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.del Álamo D, Rouault H, Schweisguth F. Mechanism and significance of cis-inhibition in Notch signalling. Curr Biol. 2011;21(1):R40–7. doi: 10.1016/j.cub.2010.10.034 [DOI] [PubMed] [Google Scholar]
  • 14.Sprinzak D, Lakhanpal A, Lebon L, Santat LA, Fontes ME, Anderson GA, et al. Cis-interactions between Notch and Delta generate mutually exclusive signalling states. Nature. 2010;465(7294):86–90. doi: 10.1038/nature08959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chen D, Forghany Z, Liu X, Wang H, Merks RMH, Baker DA. A new model of Notch signalling: control of Notch receptor cis-inhibition via Notch ligand dimers. PLoS Comput Biol. 2023;19(1):e1010169. doi: 10.1371/journal.pcbi.1010169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Nandagopal N, Santat LA, LeBon L, Sprinzak D, Bronner ME, Elowitz MB. Dynamic ligand discrimination in the Notch signaling pathway. Cell. 2018;172(4):869–880.e19. doi: 10.1016/j.cell.2018.01.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sprinzak D, Lakhanpal A, LeBon L, Garcia-Ojalvo J, Elowitz MB. Mutual inactivation of Notch receptors and ligands facilitates developmental patterning. PLoS Comput Biol. 2011;7(6):e1002069. doi: 10.1371/journal.pcbi.1002069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 2009;137(6):1124–35. doi: 10.1016/j.cell.2009.03.025 [DOI] [PubMed] [Google Scholar]
  • 19.Pedrosa A-R, Trindade A, Fernandes A-C, Carvalho C, Gigante J, Tavares AT, et al. Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1. Arterioscler Thromb Vasc Biol. 2015;35(5):1134–46. doi: 10.1161/ATVBAHA.114.304741 [DOI] [PubMed] [Google Scholar]
  • 20.Haltom AR, Jafar-Nejad H. The multiple roles of epidermal growth factor repeat O-glycans in animal development. Glycobiology. 2015;25(10):1027–42. doi: 10.1093/glycob/cwv052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Xu E-R, Blythe EE, Fischer G, Hyvönen M. Structural analyses of von Willebrand factor C domains of collagen 2A and CCN3 reveal an alternative mode of binding to bone morphogenetic protein-2. J Biol Chem. 2017;292(30):12516–27. doi: 10.1074/jbc.M117.788992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Liu Z-J, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003;23(1):14–25. doi: 10.1128/MCB.23.1.14-25.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Roukens MG, Alloul-Ramdhani M, Baan B, Kobayashi K, Peterson-Maduro J, van Dam H, et al. Control of endothelial sprouting by a Tel-CtBP complex. Nat Cell Biol. 2010;12(10):933–42. doi: 10.1038/ncb2096 [DOI] [PubMed] [Google Scholar]
  • 24.Williams CK, Li J-L, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931–9. doi: 10.1182/blood-2005-03-1000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010;12(10):943–53. doi: 10.1038/ncb2103 [DOI] [PubMed] [Google Scholar]
  • 26.Bentley K, Gerhardt H, Bates PA. Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. J Theor Biol. 2008;250(1):25–36. doi: 10.1016/j.jtbi.2007.09.015 [DOI] [PubMed] [Google Scholar]
  • 27.Bentley K, Mariggi G, Gerhardt H, Bates PA. Tipping the balance: robustness of tip cell selection, migration and fusion in angiogenesis. PLoS Comput Biol. 2009;5(10):e1000549. doi: 10.1371/journal.pcbi.1000549 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Boareto M, Jolly MK, Ben-Jacob E, Onuchic JN. Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision. Proc Natl Acad Sci U S A. 2015;112(29):E3836–44. doi: 10.1073/pnas.1511814112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Stepanova D, Byrne HM, Maini PK, Alarcón T. A multiscale model of complex endothelial cell dynamics in early angiogenesis. PLoS Comput Biol. 2021;17(1):e1008055. doi: 10.1371/journal.pcbi.1008055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032–7. doi: 10.1038/nature05355 [DOI] [PubMed] [Google Scholar]
  • 31.Ridgway J, Zhang G, Wu Y, Stawicki S, Liang W-C, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083–7. doi: 10.1038/nature05313 [DOI] [PubMed] [Google Scholar]
  • 32.Suchting S, Freitas C, le Noble F, Benedito R, Bréant C, Duarte A, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A. 2007;104(9):3225–30. doi: 10.1073/pnas.0611177104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tiemeijer LA, Ristori T, Stassen OMJA, Ahlberg JJ, de Bijl JJJ, Chen CS, et al. Engineered patterns of Notch ligands Jag1 and Dll4 elicit differential spatial control of endothelial sprouting. iScience. 2022;25(5):104306. doi: 10.1016/j.isci.2022.104306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hadjivasiliou Z, Hunter G. Talking to your neighbors across scales: long-distance Notch signaling during patterning. Curr Top Dev Biol. 2022;150:299–334. doi: 10.1016/bs.ctdb.2022.04.002 [DOI] [PubMed] [Google Scholar]
  • 35.Kuintzle R, Santat LA, Elowitz MB. Diversity in Notch ligand-receptor signaling interactions. BioRxiv. 2024;2023.08.24.554677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Luca VC, Jude KM, Pierce NW, Nachury MV, Fischer S, Garcia KC. Structural biology. Structural basis for Notch1 engagement of Delta-like 4. Science. 2015;347(6224):847–53. doi: 10.1126/science.1261093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Luca VC, Kim BC, Ge C, Kakuda S, Wu D, Roein-Peikar M, et al. Notch-Jagged complex structure implicates a catch bond in tuning ligand sensitivity. Science. 2017;355(6331):1320–4. doi: 10.1126/science.aaf9739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Suzuki IK, Gacquer D, Van Heurck R, Kumar D, Wojno M, Bilheu A, et al. Human-specific NOTCH2NL genes expand cortical neurogenesis through Delta/Notch regulation. Cell. 2018;173(6):1370–1384.e16. doi: 10.1016/j.cell.2018.03.067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Collier JR, Monk NA, Maini PK, Lewis JH. Pattern formation by lateral inhibition with feedback: a mathematical model of delta-notch intercellular signalling. J Theor Biol. 1996;183(4):429–46. doi: 10.1006/jtbi.1996.0233 [DOI] [PubMed] [Google Scholar]
  • 40.Wappner M, Uriu K, Oates AC, Morelli LG. Multiple Notch ligands in the synchronization of the segmentation clock. arXiv preprint arXiv. 2024:2408.04027. [DOI] [PubMed] [Google Scholar]
  • 41.Boareto M, Jolly MK, Lu M, Onuchic JN, Clementi C, Ben-Jacob E. Jagged-Delta asymmetry in Notch signaling can give rise to a sender/receiver hybrid phenotype. Proc Natl Acad Sci U S A. 2015;112(5):E402–9. doi: 10.1073/pnas.1416287112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Boas SEM, Merks RMH. Tip cell overtaking occurs as a side effect of sprouting in computational models of angiogenesis. BMC Syst Biol. 2015;9:86. doi: 10.1186/s12918-015-0230-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Nandagopal N, Santat LA, Elowitz MB. Cis-activation in the Notch signaling pathway. Elife. 2019;8:e37880. doi: 10.7554/eLife.37880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Page DJ, Thuret R, Venkatraman L, Takahashi T, Bentley K, Herbert SP. Positive feedback defines the timing, magnitude, and robustness of angiogenesis. Cell Rep. 2019;27(11):3139–3151.e5. doi: 10.1016/j.celrep.2019.05.052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi: 10.1038/nature10144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563–84. doi: 10.1146/annurev-cellbio-092910-154002 [DOI] [PubMed] [Google Scholar]
  • 47.Forghany Z, Robertson F, Lundby A, Olsen JV, Baker DA. Control of endothelial cell tube formation by Notch ligand intracellular domain interactions with activator protein 1 (AP-1). J Biol Chem. 2018;293(4):1229–42. doi: 10.1074/jbc.M117.819045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kelly DF, Lake RJ, Middelkoop TC, Fan H-Y, Artavanis-Tsakonas S, Walz T. Molecular structure and dimeric organization of the Notch extracellular domain as revealed by electron microscopy. PLoS One. 2010;5(5):e10532. doi: 10.1371/journal.pone.0010532 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 49.de Celis JF, Bray S, Garcia-Bellido A. Notch signalling regulates veinlet expression and establishes boundaries between veins and interveins in the Drosophila wing. Development. 1997;124(10):1919–28. doi: 10.1242/dev.124.10.1919 [DOI] [PubMed] [Google Scholar]
  • 50.Doherty D, Feger G, Younger-Shepherd S, Jan LY, Jan YN. Delta is a ventral to dorsal signal complementary to Serrate, another Notch ligand, in Drosophila wing formation. Genes Dev. 1996;10(4):421–34. doi: 10.1101/gad.10.4.421 [DOI] [PubMed] [Google Scholar]
  • 51.Becam I, Fiuza U-M, Arias AM, Milán M. A role of receptor Notch in ligand cis-inhibition in Drosophila. Curr Biol. 2010;20(6):554–60. doi: 10.1016/j.cub.2010.01.058 [DOI] [PubMed] [Google Scholar]
  • 52.Irvine KD. Fringe, Notch, and making developmental boundaries. Curr Opin Genet Dev. 1999;9(4):434–41. doi: 10.1016/S0959-437X(99)80066-5 [DOI] [PubMed] [Google Scholar]
  • 53.Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell. 2004;117(4):515–26. doi: 10.1016/s0092-8674(04)00451-9 [DOI] [PubMed] [Google Scholar]
  • 54.Eden E, Geva-Zatorsky N, Issaeva I, Cohen A, Dekel E, Danon T, et al. Proteome half-life dynamics in living human cells. Science. 2011;331(6018):764–8. doi: 10.1126/science.1199784 [DOI] [PubMed] [Google Scholar]
  • 55.Wang MM. Notch signaling and Notch signaling modifiers. Int J Biochem Cell Biol. 2011;43(11):1550–62. doi: 10.1016/j.biocel.2011.08.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Dhooge A, Govaerts W, Kuznetsov YuA, Meijer HGE, Sautois B. New features of the software MatContfor bifurcation analysis of dynamical systems. Math Comput Model Dyn Syst. 2008;14(2):147–75. doi: 10.1080/13873950701742754 [DOI] [Google Scholar]
  • 57.Roukens MG, Alloul-Ramdhani M, Moghadasi S, Op den Brouw M, Baker DA. Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination. Mol Cell Biol. 2008;28(13):4394–406. doi: 10.1128/MCB.01914-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Roukens MG, Alloul-Ramdhani M, Vertegaal ACO, Anvarian Z, Balog CIA, Deelder AM, et al. Identification of a new site of sumoylation on Tel (ETV6) uncovers a PIAS-dependent mode of regulating Tel function. Mol Cell Biol. 2008;28(7):2342–57. doi: 10.1128/MCB.01159-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Comput Biol. doi: 10.1371/journal.pcbi.1012825.r002

Decision Letter 0

Jason M Haugh, James R Faeder

12 Nov 2024

PCOMPBIOL-D-24-01720A new model of Notch signalling: evidence of a role for Notch ligand heterodimerizationPLOS Computational Biology Dear Dr. Baker, Thank you for submitting your manuscript to PLOS Computational Biology. After careful consideration, we feel that it has merit but does not fully meet PLOS Computational Biology's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please note that one reviewer has indicated that the simulation code used in this study should be made available upon publication to comply with PLOS Data policy  and we ask you to please address this point in addition to those raised in the critiques. Please submit your revised manuscript within 30 days Jan 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at ploscompbiol@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pcompbiol/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to formatting updates and technical items listed in the 'Journal Requirements' section below.* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, James R. FaederAcademic EditorPLOS Computational Biology Jason HaughSection EditorPLOS Computational Biology

Feilim Mac Gabhann

Editor-in-Chief

PLOS Computational Biology

Jason Papin

Editor-in-Chief

PLOS Computational Biology

Journal Requirements:   [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: In this manuscript, the authors develop a quantitative model for the Notch pathway that includes a novel effect of ligand heterodimerization. Through elegant experiments, they demonstrate a combinatorial effect of JAG1 and DLL1, two main ligands of the Notch pathway. They use this insight to develop a detailed biophysical model for Notch response. This work tackles the general question of combinatorial effects in signaling pathways, which is critical for understanding how cells process information from their environment. Impressively, by combining new experimental observation with quantitative modeling, the authors were able to identify an important feature of such combinatorial interactions, which has the potential to explain the differentiation of endothelial cells during angiogenic sprouting.

My main concern is about assumptions in the model that should be discussed more carefully. Specifically:

1. The authors study experimentally the capacity of DLL4, JAG1 and JAG2 to trans-activate and cis-inhibit Notch1. They show that JAG1 does not promote trans activation or cis inhibition. They then explain the first observation by lack of binding and the second observation by lack of dimer formation. Can the lack of binding itself be enough to explain both observations? While they compare the cis behavior to that of JAG2, there is no comparison of the trans behavior.

2. In the model, the author uses a single degradation parameter for all ligand monomers, dimers, and the Notch receptor. What is the motivation behind this assumption? How valid is it? Can this affect the results?

3. The model nicely describes the binding of ligands and receptors. However, it completely ignores possible reverse reactions through which complexes revert to their monomeric components. Critically, this allows the authors to solve the first two equations in (1) for D and J independently of the number of complexes or receptors. What is the justification for this assumption, and how would the result change if unbinding were allowed to occur?

Minor points:

4. While all the information is in the manuscript, writing more information within the figures could ease the reading.

- The immunoprecipitation panels could be more readable by explicitly stating the antibodies used for precipitation and staining.

- The legends show the Notch receptor as a single protein, but on the cells, two receptors bind to a single ligand. This is confusing, as the model considers a 1-1 binding between a single receptor and a single ligand.

- The cartoons for the sprouting angiogenesis simulations could gain from another panel of the in-vivo expected result for comparison.

5. Line 251: there might be a missing square root. The condition for B2 to be a small number is k_he >> \sqrt(k_ho).

Reviewer #2: The manuscript presents a development of an earlier study in PLOS Comp Bio from the same group. It provides a nice combination of cell-based assays and directed mathematical / computational modelling to explore the potential importance of homo- and hetero-dimerisation of Notch ligands in regulating the pattern of Notch signalling activity. By coupling the model of Notch ligand interactions with VEGF signalling, the model can account for the broad features of the initiation of sprouting angiogenesis.

Everything seems ok in the analysis and results. I feel that the use of "A new model of Notch signalling", as in the previous paper, is a bit of an overstatement. The effective mutual exclusion of the two unbound ligands is pretty much the same mechanism as the mutual exclusion of Notch and Delta in Sprinzak's cis inhibition model (2010, 2011), so the current results just amplify the idea that when molecules can bind into a variety of complexes, some of which are active and some inactive, then ultrasensitivity can result. I also feel that calling one's own previous recent paper "seminal" is a bit much...

Specific comments:

1. The authors should provide a bit more information about the simulations. For Fig 5A,B, where exactly is y = y_0 (used in the exponential decay function)? It is not clear. Also, how exactly does the coordinate y relate to the cell rows? It is not clear in the manuscript. For the simulations, what were the initial and boundary conditions used?

2. In Fig. 5A,B, it isn't clear to me why the authors chose conditions that restrict Notch activation to the first row of cells, so we have simulations where nothing much is happening in most of the cells. What happens if the VEGF gradient is shallower / longer-range? As it is, the model shows a lateral inhibition-like pattern in row 1 (sometimes also row 2); would this emerge in more rows of cells for a shallower VEGF gradient? It is also not clear how that pattern of Notch signalling activity translates to the biology of sprouting angiogenesis. I understand that this corresponds to the selection of tip cells, but is the period-2 spacing appropriate for the real system? Is the initial pattern of Notch activity period-2 in reality, or is it longer-range (as is typically the case? A bit more information to link the simulations to the target system would be helpful.

3. Fig. 4 shows slices through the (b_D, b_J) plane. Would it be possible to present a full picture of NICD across the plane (a 2D plot)? I think I know what it will look like, but it would be good to see how NICD depends on the full range of production rates.

4. In this model, as with the Sprinzak model of cis- and trans- binding, binding is assumed to be irreversible. So Notch and its ligands form cis- complexes that never dissociate. I think it would be good to state this assumption. I presume those complexes are going somewhere. Should I assume they are degraded / endocytosed?

5. Equation (6) is really an approximation (the authors use the expression "reduces to", but that would strictly only be in the limit). I think it should be written as such.

6. On line 343, I think the statement that the model "correctly predicts" is an overstatement; that relationship between VEGFR2 activity and high DLL4 expression is put in the model (the production rate of DLL4 is an increasing Hill function of VEGFR2 activity...)

7. The use of "expression" on line 346 is unhelpfully vague. I can't work out what the authors mean here. I think expression refers to the steady state amount of free ligands in the plasma membrane, since the production rates of ligands (what one might expect to be meant by "expression") are spatially uniform. This may seem a bit semantic, but I think it is important to be clear here, since it is at the heart of the proposed patterning mechanism.

8. A couple of minor typos: On line 455, "principle" should be "principal". In Table 1, "typic" should be "typical"

Reviewer #3: The work tackles an important question regarding cis-inhibition and is valuable for the field. The biochemical approach to studying cis-inhibition is simple but effective. The computational model nicely integrates the findings and makes interesting predictions. However, some technical and conceptual issues need to be addressed to support some of the claims and to improve the readability.

1) At which cell confluency was the cis-inhibition experiments performed? The authors should at least briefly explain whether they would expect co-expressing ligands in the “receiver” cells to increase the transactivation between two adjacent “receiver” cells and whether they considered the cell confluency as a factor that can convolute the experimental results.

2) In general, figures with Western blot images need further clarification and addition of the necessary controls. Please see below:

In Figure 1D, the size of all three Notch paralogs seems to be the same, even though the Notch3 receptor should be about 20kD smaller. The authors should explain what this band corresponds to and perhaps show the full membrane together with the protein ladder in the supplementary data. The size of the bands, and blots of an appropriate housekeeping protein should be added. Additionally, the blots are mis-aligned and do not match the sample labels properly.

While how the receptor and the ligand constructs were tagged were explained in the methods section, it is difficult to understand the construct identity this by looking at the figure, since only the tag names are shown. Adding this information to the figures either in the cartoons or on the blots is recommended.

Figure 2: The blots from the immunoprecipitation experiments are difficult to understand. The authors should annotate the blots with the information which proteins were pulled down and what they were probed for afterwards (e.g. IP:His, WB: His and IP:His, WB:HA) to make them easier for the reader to understand.

Figure 5S: Considering the Notch1 construct was tagged in the C-terminal, wouldn´t the authors expect to see the cleavage products of the Notch receptor in their blots when it is activated by the ligand-expressing cells? Judging by the Dll4, Jagged1, Notch1 co-blots the authors are only showing the full length Notch1 precursor. Additionally, the authors should again annotate the protein size on these blots, and possibly blot the same samples for the cleaved NICD to further support the reporter assay results if it is not possible to visualize the cleavage products otherwise.

3) Line 832, 836, 851, 854: “tissue-culture cells” sounds off. Please revise.

4) There seems to be major issues relating to the coherence of the manuscript. For example, the use of the Notch3 ECD protein and of DAPT as a control condition for the luciferase assays were elusive in the text and in the figures, even though they were mentioned in the material and methods section(?). The authors must make sure that the writing is consistent with the figures.

5) For all figures, the appropriate statistic tests should be done for the experimental data, and corresponding graphs should be annotated with the results.

Further deficiencies:

• Figures need to be organized better. In some cases, they lack necessary information.

• Issues with consistency between the text and the data.

The manuscript requires

• Additional experiments

• Additional information

• Revision of the text

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No:  I can't see any information on availability of the code used for simulations.

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols  

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1012825.r004

Decision Letter 1

Jason M Haugh, James R Faeder

25 Jan 2025

Dear Dr Baker,

We are pleased to inform you that your manuscript 'A model of Notch signalling control of angiogenesis: evidence of a role for Notch ligand heterodimerization' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

James R Faeder

Academic Editor

PLOS Computational Biology

Jason Haugh

Section Editor

PLOS Computational Biology

***********************************************************

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors have adequately addressed my concerns. The paper addresses an important question in a rigorous manner, and should be published.

My only comment is a small typo. In Line 149, I believe that the phrase “(and JAG2)” seems out of place.

Reviewer #2: The authors have revised the manuscript in a way that addresses all the points I made in the first round of review. I am therefore happy to recommend acceptance for publication.

Reviewer #3: The authors have appropriately addressed the reviewers comments and I am happy to accept the manuscript for publication.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: None

Reviewer #2: Yes

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1012825.r005

Acceptance letter

James Faeder

PCOMPBIOL-D-24-01720R1

A model of Notch signalling control of angiogenesis: evidence of a role for Notch ligand heterodimerization

Dear Dr Baker,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Zsofia Freund

PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom ploscompbiol@plos.org | Phone +44 (0) 1223-442824 | ploscompbiol.org | @PLOSCompBiol

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. JAG1 efficiently binds to Notch1 in cis.

    293T cells were co-transfected with the indicated combinations of HA epitope-tagged JAG1 and HIS6 epitope-tagged Notch. Ligands were resolved using an anti-HA antibody and ligand-receptor complexes were determined by Western blotting with the indicated antibodies.

    (EPS)

    S2 Fig. Cis DLL4-JAG1 heterodimerization enables efficient trans DLL4-dependent cleavage of Notch.

    293T cells expressing, in cis, the indicated combinations of HA epitope-tagged Notch, FLAG epitope-tagged DLL4 or HIS6 epitope-tagged JAG1, were cultured in the presence or absence of recombinant (trans) DLL4 for the indicated time-course. Cells were cultured in 6 cm dishes and lysed directly in denaturing Laemmli buffer to enable detection of processed Notch. Notch receptor cleavage was monitored by Western blotting with an anti-HA antibody. Expression levels of DLL4, JAG and the housekeeping gene, Vinculin, were determined by Western blotting with the indicated antibodies. DLL4-(EGF7) lacks the EGF-like repeat 7.

    (EPS)

    pcbi.1012825.s002.eps (1.4MB, eps)
    S3 Fig. Mutual inactivation of DLL4 and JAG1 in the same cell.

    (A) The simulation is based on the DLL4/JAG1-Notch signalling model (1) with strong DLL4-JAG1 heterodimerization (khe=0.1). The production rate of DLL4 in the cell is fixed at bD=100. (B) The simulation was performed under the same conditions, but the dissociation of the DLL4 homodimer was taken into account.

    (TIFF)

    pcbi.1012825.s003.tiff (3.1MB, tiff)
    S4 Fig. Two-dimensional simulations of the results presented in.

    Fig 4. The relative levels of Notch activity (NICD) in response to different production rates of: (A and B) cis-DLL4 (bD)/JAG1 (bJ), and (C–F) trans-DLL4 (bD)/JAG1 (bJ), across the two-dimensional plane (bD, bJ).

    (TIFF)

    pcbi.1012825.s004.tiff (16.6MB, tiff)
    S5 Fig. Extended simulations of the results presented in.

    Fig 4. (A–C) Notch activity in the receiving cell as a function of cis-ligand production rates. (D–H) Notch activity in the receiving cell as a function of trans-ligand production rates. The degradation rates of ligand monomer, ligand dimer and Notch receptor are independently assumed to be: 0.05/h (a half-life of about 14 hours), 0.15/h (a half-life of about 5 hours), or 0.25/h (a half-life of about 3 hours).

    (TIFF)

    pcbi.1012825.s005.tiff (9.4MB, tiff)
    S6 Fig. Extended simulations of the cellular patterning described in Fig 5A.

    The simulations were performed with a shallower VEGF gradient. The VEGF concentration was set according to: (A) Vy=Vext/exp2y−y0; (B) Vy=Vext/exp5y−y0; C) Vy=Vext/exp35y−y0. See Numerical simulations (Methods) for simulation information.

    (TIF)

    pcbi.1012825.s006.tif (7.4MB, tif)
    S7 Fig. (A) Diagrammatic representation of the effects of JAG1 and DLL4 on endothelial cell behaviours.

    DLL4 inhibits sprouting angiogenesis whereas JAG1 promotes it. (B) Bifurcation diagram of VEGFR2 activity in either of two interacting cells driven by DLL4 production rate in the cells. The simulations are based on the DLL4/JAG1-Notch-VEGF signalling model (2) by assuming that there is no DLL4-JAG1 heterodimerization in the cells. In this scenario, the variation of JAG1 production rate does not affect the bifurcation diagram driven by DLL4 production rate.

    (TIFF)

    pcbi.1012825.s007.tiff (6.8MB, tiff)
    S8 Fig. Differential affinities of JAG1-DLL4 and DLL4-DLL4 interactions.

    (A) HIS epitope tagged DLL4 immunopurified from 293T cells using nickel-NTA agarose was incubated with the indicated combinations of (cell-expressed) HA epitope tagged DLL4 and JAG1. Protein Interactions were determined by Western blotting with the indicated antibodies. (B) Quantification of the bands shown in (A).

    (EPS)

    pcbi.1012825.s008.eps (2.8MB, eps)
    S9 Fig. A DLL4-JAG1 heterodimer blocks DLL4-mediated Notch2 and Notch3 receptor cis inhibition and enables efficient Notch2 and Notch3 receptor transactivation.

    (A) Schematic representation of luciferase reporter assays performed as described in the Methods. (B) 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch2 receptor and ligand constructs (stalk cells) were co-cultured with cells stably expressing DLL4 (tip cells) to enable transactivation. DLL4-Δ(EGF7) and DLL4-Δ(EGF8) lack the EGF-like repeat 7 and the EGF-like repeat 8 (see Fig 3C), respectively. For each analysis, reporter activity was normalized using Renilla luciferase. Levels of ectopically expressed proteins were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown. (C) 293T cells co-expressing a Notch activity luciferase reporter together with the indicated Notch3 receptor and ligand constructs (stalk cells) were co-cultured with cells stably expressing DLL4 (tip cells) to enable transactivation. DLL4-Δ(EGF7) and DLL4-Δ(EGF8) lack the EGF-like repeat 7 and the EGF-like repeat 8 (see Fig 3C), respectively. For each analysis, reporter activity was normalized using Renilla luciferase. Levels of ectopically expressed proteins were determined by Western blotting of cell lysates. Each condition in each experiment was performed in triplicate and error bars represent the standard deviation of the mean. Experiments were performed three times. Representative experiments are shown.

    (EPS)

    pcbi.1012825.s009.eps (3.2MB, eps)
    S10 Fig. Protein levels of Notch receptors and ligands were determined by Western blotting of lysates corresponding to the following luciferase reporter assays: (A) Fig 1A.

    (B) Fig 2A. (C) Fig 2E. (D) Fig 3B. (E) Fig 3E.

    (EPS)

    pcbi.1012825.s010.eps (9.5MB, eps)
    S1 Video. Multicellular simulations of tip/stalk cell patterning in sprouting angiogenesis.

    This video corresponds to Fig 5A with DLL4-JAG1 heterodimerization.

    (GIF)

    pcbi.1012825.s011.gif (6.8MB, gif)
    S2 Video. Multicellular simulations of tip/stalk cell patterning in sprouting angiogenesis.

    This video corresponds to Fig 5B without DLL4-JAG1 heterodimerization.

    (GIF)

    Attachment

    Submitted filename: Chen et al. REVISION Cover letter 10.12.24.docx

    pcbi.1012825.s014.docx (37.2KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files. Code running on MATLAB R2021a can be accessed via: https://github.com/DaipengChen/Notch-Angiogenesis.


    Articles from PLOS Computational Biology are provided here courtesy of PLOS

    RESOURCES